CompletedPhase 3NCT01412424

Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

Studying Acromegaly

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Chiasma, Inc.
Principal Investigator: Shlomo Melmed, MD
Cedars-Sinai Medical Center
Intervention: Octreotide capsules(drug)
Enrollment: 155 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2012 – 2014

Study locations (30)

Cedars-Sinai Medical Center, Los Angeles, California, United States
Campus Charité Mitte, Berlin, Germany
ENDOC Center for Endocrine Tumors, Hamburg, Germany
Medizinische Klinik Innenstadt, Munich, Germany
Max Planck Institute of Psychiatry, Munich, Germany
Praxis for Endocrimology and Diabetology in Oldenburg, Oldenburg, Germany
Military Hospital, State Health Center 2nd Department of Internal Medicine, Budapest, Hungary
Semmelweiss University, Budapest, Hungary
University of Pecs, Pécs, Hungary
University of Szeged, Szeged, Hungary
Servizio di Endocrinologia A.O. Spedali Civili di Brescia, Brescia, Italy
Dipartimento Clinico Sperimentale di Medicina e Farmacologia, Messina, Italy
Ospedale Molinette, Torino, Italy
Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania
Vilnius University Hospital Santariskiu Clinics Center of Endocrinology, Vilnius, Lithuania
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01412424 on ClinicalTrials.gov

Other trials for Acromegaly

Additional recruiting or active studies for the same condition.

See all trials for Acromegaly →

← Back to all trials